KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Globus Medical (GMED) Gains from Sales and Divestitures (2023 - 2025)

Globus Medical's Gains from Sales and Divestitures history spans 3 years, with the latest figure at $117000.0 for Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures fell 66.86% year-over-year to $117000.0; the TTM value through Sep 2025 reached $117000.0, down 66.86%, while the annual FY2024 figure was $18000.0, 800.0% up from the prior year.
  • Gains from Sales and Divestitures reached $117000.0 in Q3 2025 per GMED's latest filing, up from $20000.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $432000.0 in Q3 2023 to a low of $2000.0 in Q4 2023.
  • Average Gains from Sales and Divestitures over 3 years is $139222.2, with a median of $20000.0 recorded in 2025.
  • Peak YoY movement for Gains from Sales and Divestitures: soared 800.0% in 2024, then crashed 93.42% in 2025.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $2000.0 in 2023, then skyrocketed by 800.0% to $18000.0 in 2024, then skyrocketed by 550.0% to $117000.0 in 2025.
  • Per Business Quant, the three most recent readings for GMED's Gains from Sales and Divestitures are $117000.0 (Q3 2025), $20000.0 (Q2 2025), and $2000.0 (Q1 2025).